Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
A-POXIDE vs BIAXIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GABA-A receptor positive allosteric modulator; increases chloride ion influx and neuronal hyperpolarization.
Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis by blocking peptide chain elongation.
Anxiety disorders,Alcohol withdrawal syndrome,Seizure disorders (adjunctive),Preoperative sedation
Acute bacterial exacerbation of chronic bronchitis,Acute maxillary sinusitis,Community-acquired pneumonia,Pharyngitis/tonsillitis,Uncomplicated skin and skin structure infections,Helicobacter pylori eradication (as part of triple or dual therapy),Mycobacterium avium complex prophylaxis and treatment (off-label for some indications)
GERD: 20 mg orally once daily for 4-8 weeks. Erosive esophagitis: 40 mg once daily for 8 weeks. H. pylori eradication: 20 mg twice daily with amoxicillin and clarithromycin for 14 days.
250-500 mg orally every 12 hours for 7-14 days; extended-release: 1000 mg orally every 24 hours for 7-14 days
Terminal elimination half-life is 12-18 hours (mean 15 hours) in adults with normal renal function. Prolonged to 24-36 hours in elderly or moderate renal impairment (Cr Cl < 50 m L/min).
Terminal elimination half-life: 3-7 hours (single dose, 250-500 mg); with multiple dosing, half-life may extend to 7-10 hours due to saturable metabolism. Clinical context: Shorter half-life requires twice-daily dosing; extended half-life (via 14-hydroxy metabolite, t1/2 ~11 h) contributes to antibacterial activity.
Extensively metabolized in the liver via CYP2C19 (major) and CYP3A4 (minor) to inactive metabolites. CYP2C19 polymorphisms significantly affect clearance.
Primarily metabolized by CYP3A4 isoenzyme; clarithromycin undergoes first-pass metabolism to form 14-hydroxyclarithromycin (active metabolite).
Renal excretion accounts for 60-70% of elimination, predominantly as unchanged drug. Biliary/fecal excretion accounts for 20-30%, with approximately 10% eliminated in feces as metabolites.
Approximately 20-30% of administered dose is excreted unchanged in urine; remainder is hepatically metabolized and excreted in bile and feces (~50% fecal elimination).
95% bound to albumin.
65-75% bound, primarily to albumin and alpha-1-acid glycoprotein.
Volume of distribution is 0.8-1.2 L/kg, indicating extensive distribution into total body water with accumulation in tissues (brain, liver, kidneys).
Vd: 2.6-3.5 L/kg. Clinical meaning: Large Vd indicates extensive tissue penetration, including lungs, tonsils, and sinuses, exceeding serum concentrations.
Oral: 80-90%; Intramuscular: 95-100%; no data for other routes.
Oral bioavailability: 50-55% (250 mg tablet); may be increased to 60-70% when administered with food. Intravenous: 100%.
No dosage adjustment required for mild-to-moderate renal impairment (Cr Cl >30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), maximum dose 20 mg daily.
Cr Cl <30 m L/min: reduce dose by 50%; Cr Cl <10 m L/min: not recommended; no adjustment for Cr Cl >30 m L/min
Mild impairment: no adjustment. Moderate-to-severe (Child-Pugh B/C): maximum dose 20 mg daily.
Child-Pugh Class C: reduce dose by 50% or consider alternative; mild to moderate hepatic impairment: no adjustment
Approved for GERD in children ≥1 year (weight-based: 0.5-1 mg/kg once daily; maximum 20 mg). Safety in infants <1 year not established.
15 mg/kg/day orally divided every 12 hours; maximum 500 mg/day for 10 days; for extended-release, not recommended for children <12 years
No specific dose adjustment, but monitor renal function and for increased risk of Clostridium difficile infection and osteoporosis-related fractures.
No specific dose adjustment; monitor renal function and adjust per renal guidelines; increased risk of QT prolongation
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve use for patients with inadequate alternatives.
None
Risk of dependence and withdrawal reactions; avoid abrupt discontinuation. May cause CNS depression and impair cognitive function. Use caution in hepatic impairment and geriatric patients.
Increased risk of cardiac arrhythmias, including QT prolongation and torsades de pointes; avoid in patients with known QT prolongation or concurrent use with QT-prolonging drugs.,Potential for hepatotoxicity (elevated liver enzymes, hepatitis); monitor liver function.,Exacerbation of myasthenia gravis symptoms.,Clostridioides difficile-associated diarrhea (CDAD).,Drug interactions via CYP3A4 inhibition (e.g., statins, warfarin, colchicine, and other macrolides).,Pregnancy Category C; avoid use unless no alternative (clarithromycin associated with increased risk of miscarriage and fetal abnormalities in animal studies).
Severe hepatic impairment, acute narrow-angle glaucoma, myasthenia gravis, hypersensitivity to benzodiazepines, concurrent use with potent CYP3A4 inhibitors.
Hypersensitivity to clarithromycin, erythromycin, or any macrolide antibiotic.,Concurrent use with pimozide, ergotamine, dihydroergotamine, lovastatin, simvastatin, or colchicine in renal/hepatic impairment.,History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use.,QT prolongation or history of ventricular arrhythmias (including torsades de pointes).,Concurrent use with antiarrhythmics (e.g., quinidine, procainamide, amiodarone) or other QT-prolonging drugs.,Severe hepatic failure or acute porphyria.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Avoid alcohol. Taking with food may delay absorption but does not affect total bioavailability.
Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4 and may increase clarithromycin levels, raising risk of QT prolongation. High-fat meals may delay absorption but do not significantly alter total exposure. Alcohol is not specifically contraindicated but may increase gastrointestinal irritation; avoid concurrent use of statins (especially simvastatin, lovastatin) due to increased myopathy risk.
First trimester: Risk of major malformations (neural tube defects, cleft palate) increased by 2-3 fold. Second/third trimester: Risk of preterm birth, low birth weight, and neonatal withdrawal syndrome. Chronic use: Fetal hydantoin syndrome (craniofacial anomalies, growth deficiency, intellectual disability).
FDA Pregnancy Category C. Animal studies have shown fetal harm (cleft palate, skeletal abnormalities) at doses 2-5 times the human clinical dose. No adequate human studies. First trimester: Avoid unless benefit justifies risk. Second and third trimesters: Limited data; use only if clearly needed. Monitor for potential maternal hepatotoxicity.
Excreted into breast milk; M/P ratio ~0.3-0.5. Infant serum levels may reach subtherapeutic concentrations. Risk of sedation and poor feeding. Consider risk-benefit; monitor infant for drowsiness and weight gain.
Clarithromycin is excreted into human breast milk; the milk-to-plasma ratio is approximately 0.25-0.5. Infants exposed via breast milk may experience gastrointestinal disturbances or altered gut flora. Use with caution, especially in infants younger than 6 weeks of age due to risk of hypertrophic pyloric stenosis. Consider temporary discontinuation during therapy if high doses are used.
Enhanced clearance (up to 50% increase) in pregnancy requires dose adjustments to maintain therapeutic levels. Frequent monitoring of free phenytoin levels recommended; total levels may be misleading due to decreased albumin. Postpartum dose reduction likely needed.
No specific pharmacokinetic studies have demonstrated a need for dose adjustment during pregnancy. However, pregnancy can increase volume of distribution and renal clearance; empirical dose monitoring is not required. Standard dosing regimens are applied unless hepatic or renal impairment is present.
A-POXIDE is a potent benzodiazepine with rapid onset; use lowest effective dose to minimize tolerance. Monitor for respiratory depression, especially in elderly or those with COPD. Abrupt discontinuation may cause withdrawal seizures; taper gradually over weeks to months. Avoid concurrent use with other CNS depressants including alcohol.
Biaxin (clarithromycin) is a macrolide antibiotic with activity against atypical pathogens (e.g., Legionella, Mycoplasma, Chlamydia). It is a potent CYP3A4 inhibitor, increasing levels of statins, warfarin, and colchicine. Use caution in myasthenia gravis; may exacerbate weakness. QT prolongation risk: avoid use with other QT-prolonging drugs, correct electrolyte abnormalities. For H. pylori eradication, combine with amoxicillin and a PPI as first-line. Renal dose adjustment required for Cr Cl <30 m L/min.
Do not consume alcohol while taking this medication.,May cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Do not stop taking abruptly; follow your doctor's instructions for tapering the dose.,Inform your doctor if you have a history of substance abuse or respiratory conditions.,Store at room temperature away from moisture and heat.,Take exactly as prescribed; do not increase dose without consulting your doctor.
Take with or without food, but taking with food may reduce stomach upset.,Complete the full course even if you feel better to prevent resistance.,Avoid grapefruit or grapefruit juice while on this medication.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, severe nausea/vomiting.,May cause metallic or bitter taste in the mouth; this is usually temporary.,Tell your doctor if you have myasthenia gravis, as clarithromycin can worsen symptoms.,Avoid driving or operating heavy machinery if you experience dizziness or vision changes.,Use effective contraception if applicable; clarithromycin may reduce oral contraceptive efficacy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about A-POXIDE vs BIAXIN, answered by our medical review team.
A-POXIDE is a Benzodiazepine that works by GABA-A receptor positive allosteric modulator; increases chloride ion influx and neuronal hyperpolarization.. BIAXIN is a Macrolide Antibiotic that works by Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis by blocking peptide chain elongation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between A-POXIDE and BIAXIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of A-POXIDE is: GERD: 20 mg orally once daily for 4-8 weeks. Erosive esophagitis: 40 mg once daily for 8 weeks. H. pylori eradication: 20 mg twice daily with amoxicillin and clarithromycin for 14 days.. The standard adult dose of BIAXIN is: 250-500 mg orally every 12 hours for 7-14 days; extended-release: 1000 mg orally every 24 hours for 7-14 days. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between A-POXIDE and BIAXIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. A-POXIDE is classified as Category C. First trimester: Risk of major malformations (neural tube defects, cleft palate) increased by 2-3 fold. Second/third trimester: Risk of preterm birth, low birth weight, and neonata. BIAXIN is classified as Category C. FDA Pregnancy Category C. Animal studies have shown fetal harm (cleft palate, skeletal abnormalities) at doses 2-5 times the human clinical dose. No adequate human studies. First t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.